Unknown

Dataset Information

0

Antiviral Effect of Budesonide against SARS-CoV-2.


ABSTRACT: Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.

SUBMITTER: Heinen N 

PROVIDER: S-EPMC8310374 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiviral Effect of Budesonide against SARS-CoV-2.

Heinen Natalie N   Meister Toni Luise TL   Klöhn Mara M   Steinmann Eike E   Todt Daniel D   Pfaender Stephanie S  

Viruses 20210720 7


Treatment options for COVID-19, a disease caused by <i>Severe</i>&nbsp;<i>Acute</i>&nbsp;<i>Respiratory</i>&nbsp;<i>Syndrome</i> Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases  ...[more]

Similar Datasets

| S-EPMC9717461 | biostudies-literature
| S-SCDT-10_1038-S44319-024-00189-4 | biostudies-other
| S-EPMC10719564 | biostudies-literature
| S-EPMC7354438 | biostudies-literature
| S-EPMC8402917 | biostudies-literature
| S-EPMC7605242 | biostudies-literature
| S-EPMC9906591 | biostudies-literature
2024-08-14 | GSE274550 | GEO
| S-EPMC10179150 | biostudies-literature
| S-EPMC10569654 | biostudies-literature